Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments

Current Oncology Reports

Volumn 17, Issue 4, 2015, Pages

  Stover, Daniel G ^a   Wagle, Nikhil ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Breast cancer; Genomics; Personalized medicine; Precision cancer medicine; Sequencing

Indexed keywords

B RAF KINASE; ESTROGEN RECEPTOR; FIZZY RELATED PROTEIN; K RAS PROTEIN; MAP3K1 PROTEIN; MLL3 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR GATA 3; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; BRAF PROTEIN, HUMAN; TUMOR MARKER;

BREAST CANCER; BREAST CARCINOMA; BREAST FIBROADENOMA; BREAST METASTASIS; CANCER PROGNOSIS; CHROMOSOME BREAKAGE; CIRCULATING TUMOR CELL; COPY NUMBER VARIATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC SCREENING; GENOMICS; GENOTYPE; HUMAN; HUMAN GENOME; HUMAN GENOME PROJECT; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; NEXT GENERATION SEQUENCING; NONSENSE MUTATION; ONCOGENE; POINT MUTATION; RECEPTOR BINDING ASSAY; REVIEW; SANGER SEQUENCING; SOMATIC MUTATION; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; FEMALE; GENETICS; MOLECULARLY TARGETED THERAPY; MUTATION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; TRENDS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84923673213     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-015-0438-0     Document Type: Review

References (94)

1. SEER Cancer Statistics Factsheets: Breast Cancer. National Cancer Institute, 2014. (Accessed July 3, 2014, at http://seer.cancer.gov/statfacts/html/breast.html.)
2. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153:17–37.
3. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31:1806–14.
4. MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31:1815–24.
5. Knight WA, Livingston RB, Gregory EJ, McGuire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977;37:4669–71.
6. Fisher B, Redmond C, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6.
7. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981;304:16–21.
8. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol: Off J Ame Soc Clin Oncol. 1999;17:1474–81.
9. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319:1239–45.
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.
11. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.
12. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.
13. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–23.
14. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.
15. van ‘t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.
16. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452:564–70.
17. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42.
18. Krop I, Winer EP. Further progress in HER2-directed therapy. Lancet Oncol. 2012;13:2–3.
19. Wagle N, Van Allen EM, Treacy DJ, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014;4:61–8.
20. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. The New England journal of medicine 2014.
21. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703.
22. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189–97.
23. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. The New England journal of medicine 2014.
24. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347–51.
25. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–8.
26. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869–73.
27. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
28. Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31:1097–104.
29. Ali SM, Alpaugh RK, Buell JK, et al. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clin Breast Cancer. 2014;14:e14–6. In this case report, a patient with advanced HER2+ inflammatory breast cancer, that had developed resistance to HER2-targeted therapy was found by genomic profiling to have an L858R base substitution in EGFR, a well-known activating mutation in non-small cell lung cancer. Treatment with erlotinib, an EGFR-targeted therapy approved in NSCLC, was effective, with an 8-month period of cancer regression as well as symptomatic improvement. This case report is an example of how genomic profiling can identify targeted therapies that otherwise might not be considered for patients with breast cancer.
30. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11:685–96.
31. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146–58.
32. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009;4:e7887.
33. Johnson DB, Dahlman KH, Knol J, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist. 2014;19:616–22.
34. MacConaill LE, Garcia E, Shivdasani P, et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn: JMD. 2014;16:660–72.
35. Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31:1825–33.
36. Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012;2:82–93.
37. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
38. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486:400–4.
39. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395–9.
40. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486:405–9.
41. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486:353–60.
42. Polyak K, Metzger FO. SnapShot: breast cancer. Cancer Cell. 2012;22:562–e1.
43. Natrajan R, Mackay A, Lambros MB, et al. A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. J Pathol. 2012;227:29–41.
44. De Brot M, Andrade V, Morrogh M, et al. Novel mutations in lobular carcinoma in situ (LCIS) as uncovered by targeted parallel sequencing. Cancer research 2012;72
45. Lim WK, Ong CK, Tan J, et al. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet. 2014;46:877–80.
46. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.
47. Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010;463:893–8.
48. Blackwell K, Hamilton E, Marcom P, et al. Abstract S4-03: Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer. Cancer Res. 2013;73:S4–S03.
49. Wagle N, Lin NU, Richardson AL, et al. Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. ASCO Meet Abstr. 2014;32:536.
50. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.
51. Vaz-Luis I, Zeghibe CA, Frank ES, et al. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013;142:203–9.
52. Andre F, Bachelot TD, Campone M, et al. Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01). ASCO Meet Abstr. 2013;31:511.
53. Andre F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014;15:267–74. The SAFIR01 study evaluated 423 patients with metastatic breast cancer, identifying a targetable genomic alteration in 195 patients (46%). While only a small subset – 55 patients (13%) received ‘personalized’ therapy, this trial provides a proof of concept for incorporating genomic analyses into clinical studies.
54. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3:111ra21.
55. Zardavas D, Maetens M, Irrthum A, et al. The AURORA initiative for metastatic breast cancer. Br J Cancer 2014. The AURORA initiative is a prospective study that will perform next generation sequencing for a panel of cancer-related genes on tumour tissue and blood samples from patients with meastatic breast cancer, then follow them longitudinally. This multi-national study hopes to direct patients into clinical trials based on their genomic characteristics, while also collecting information about long-term outcomes for this cohort
56. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20:682–8.
57. Conley BA, Doroshow JH. Molecular Analysis for Therapy Choice: NCI MATCH. Semin Oncol. 2014;41:297–9.
58. Everett JN, Gustafson SL, Raymond VM. Traditional roles in a non-traditional setting: genetic counseling in precision oncology. J Genet Couns. 2014;23:655–60.
59. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. JClin Oncol: Off J Am Soc Clin Oncol. 2013;31:1834–41.
60. Slosberg ED, Kang B, Beck JT, et al. The signature program, a series of tissue-agnostic, mutation-specific signal finding trials. ASCO Meet Abstr. 2014;32:TPS2646.
61. Balko JM, Giltnane JM, Wang K, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4:232–45.
62. Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Cli Cancer Res: Off J Am Assoc Cancer Res. 2014;20:1757–67.
63. Li S, Shen D, Shao J, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4:1116–30.
64. Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446–51. These two studies demonstrated mutations in the estrogen receptor gene, ESR1, as a novel mechanism of resistance to hormonal therapy in breast cancer. This observation illuminates the importance of genomic characterization not just for potential susceptibilities but also resistance to therapy.
65. Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439–45. These two studies demonstrated mutations in the estrogen receptor gene, ESR1, as a novel mechanism of resistance to hormonal therapy in breast cancer. This observation illuminates the importance of genomic characterization not just for potential susceptibilities but also resistance to therapy.
66. Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345:216–20.
67. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al. D538G mutation in estrogen receptor-alpha: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013;73:6856–64.
68. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3:224–37.
69. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9:16–32.
70. Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4:546–53.
71. Wagle N, Grabiner BC, Van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371:1426–33.
72. Abrams J, Conley B, Mooney M, et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting 2014:71–6
73. Al-Ahmadie H, Iyer G, Hohl M, et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov. 2014;4:1014–21.
74. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338:221.
75. Rath MG, Masciari S, Gelman R, et al. Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat. 2013;139:193–8.
76. Dewey FE, Grove ME, Pan C, et al. Clinical interpretation and implications of whole-genome sequencing. JAMA. 2014;311:1035–45. An evaluation of whole genome sequencing on 12 patients reveals the challenges of sequencing the whole genome - incomplete coverage and low reproducibility of known disease-associated genetic variants with difficulty determining what findings to convey to patients. This supports a multiplexed, targeted sequencing approach of actionable genes for tumors rather than whole genome sequencing.
77. Swanton C, Burrell RA, Futreal PA. Breast cancer genome heterogeneity: a challenge to personalised medicine? Breast Cancer Res. 2011;13:104.
78. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461:809–13.
79. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464:999–1005.
80. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46:225–33.
81. Nik-Zainal S, Van Loo P, Wedge DC, et al. The life history of 21 breast cancers. Cell. 2012;149:994–1007.
82. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90–4.
83. Wang Y, Waters J, Leung ML, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512:155–60.
84. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153–8.
85. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463:191–6.
86. Nik-Zainal S, Alexandrov LB, Wedge DC, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149:979–93.
87. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.
88. Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014;32:479–84.
89. Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110–22.
90. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011;192:373–82.
91. Dawson SJ, Rosenfeld N, Caldas C. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;369:93–4.
92. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199–209.
93. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2014.
94. van Rooij N, van Buuren MM, Philips D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31:e439–42.